ADCs moving towards brain

Antibody–drug conjugates in brain tumours

Read our June issue to learn more about the activity of ADCs in primary and secondary brain tumours

  • Maximilian J. Mair
  • Rupert Bartsch
  • Matthias Preusser
Review Article

Featured

  • Bladder cancer is among the ten most common cancers worldwide and therefore constitutes a substantial health-care burden. This Review summarizes the global trends in bladder cancer incidence and mortality, and describes the main risk factors associated with bladder cancer occurrence and outcomes. The implications, challenges and opportunities of these epidemiological trends for public health and clinical practice are also discussed.

    • Lisa M. C. van Hoogstraten
    • Alina Vrieling
    • Lambertus A. Kiemeney
    Review Article

  • Globally, gastric cancer is a common and highly fatal cancer with two anatomical subtypes, non-cardia and cardia gastric cancer. Helicobacter pylori causes almost 90% of distal gastric cancers worldwide. The authors of this Review summarize the current epidemiology of gastric cancer and the evidence and implications of primary and secondary prevention efforts.

    • Aaron P. Thrift
    • Theresa Nguyen Wenker
    • Hashem B. El-Serag
    Review Article

  • Advances in surgical technique and chemotherapy regimens have improved the survival outcomes of patients with pancreatic cancer, although these remain dismal relative to most other solid tumours. Attempts to further improve outcomes have led to increasing research interest in neoadjuvant therapy, which is beginning to improve the outcomes of certain subgroups of patients. In this Review, the authors provide an overview of the various neoadjuvant therapy approaches for patients with pancreatic cancer, including discussions of several promising future research directions

    • Christoph Springfeld
    • Cristina R. Ferrone
    • John Neoptolemos
    Review Article

  • Genomics-based precision medicine has improved the outcomes of patients with certain types of cancers, although most do not derive benefit. Here, the authors describe the development of functional patient-specific assays, including those based on organoids, spheroids and explants, and how clinical implementation of these models might extend the benefits of precision medicine to a much broader range of patients.

    • Allard W. J. van Renterghem
    • Joris van de Haar
    • Emile E. Voest
    Review Article

Current issue

Volume 20 Issue 6
Contents
View all issues
Subscribe

Announcements

  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic

  • five diverse women

    This regularly updated collection of articles published in the Nature Reviews journals provides in-depth discussions of recent research and medical advances in fields covering women’s health in the broadest sense.

Advertisement

Latest Reviews & Analysis

    • The effective management of treatment-related events remains an unmet need in oncology. The authors of this Review discuss the underlying biological mechanisms, risk factors, most commonly used pharmacological and non-pharmacological management strategies, and clinical practice guidelines for the most common long-term (continuing beyond treatment) and late or delayed (following treatment) adverse events associated with chemotherapy and other anticancer treatments.

      • Maryam B. Lustberg
      • Nicole M. Kuderer
      • Gary H. Lyman
      Review Article

    • Dysregulation of N6-methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, is common in various cancer types. The authors of this Review provide an overview of the mechanisms of m6A-dependent RNA regulation, summarize current knowledge of their pathological effects and potential utility as biomarkers in cancer, and describe ongoing efforts to develop small-molecule inhibitors of oncogenic m6A modifiers.

      • Xiaolan Deng
      • Ying Qing
      • Jianjun Chen
      Review Article

    • Cholangiocarcinoma is a malignancy that continues to be associated with a dismal prognosis, and a better understanding of the disease biology is required to improve early detection and treatment strategies. In this Review, the authors describe key scientific and clinical advances made in this area over the past 5 years, encompassing novel insights into the tumour stroma and immune microenvironment, promising progress in developing liquid biopsy approaches for diagnosis and monitoring, clinical translation of molecularly targeted therapies, emerging immunotherapies and reassessment of the potential role of liver transplantation.

      • Sumera I. Ilyas
      • Silvia Affo
      • Gregory J. Gores
      Review Article

    • Bispecific T cell engagers offer a novel treatment approach for patients with multiple myeloma, although mechanisms of resistance are largely unknown. Here, we discuss the implications of a recent report from Friedrich et al. that highlights the importance of pre-treatment T cell characteristics for a response to the T cell engager elranatamab and how these data might be used to inform future study and trial design.

      • Shonali Midha
      • Kenneth C. Anderson
      News & Views

    • Emerging data indicate a central role for the microbiota in all aspects of colorectal cancer (CRC). Despite this general consensus, understanding the role of specific components of the microbiota in such a way that enables the development of clinical interventions or tools to inform clinical decision-making has thus far proved challenging. In this Review, the authors summarize the role of the microbiota in CRC, including in prevention, in interactions with treatment and as a source of novel biomarkers.

      • Chi Chun Wong
      • Jun Yu
      Review Article

News & Comment

Trending - Altmetric

Nature Careers

Jobs

Advertisement